A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.
نویسندگان
چکیده
In almost all current Phase I designs, toxicity response is treated coarsely as a binary indicator of dose limiting toxicity (DLT) and a lot of useful toxicity information is discarded. We are the first to establish a novel toxicity scoring system to treat toxicity response as a quasi-continuous variable and utilize all toxicities in Phase I trial. The generally accepted and objective parts, such as a logistic function, grade and type of toxicity, and whether the toxicity is DLT, are used so that the toxicity scoring system is relatively objective. Our toxicity scoring system has been successfully applied to an isotonic design (ID) to develop an extended isotonic design (EID). Simulation study and application of EID to the data of a real Phase I trial demonstrate that EID can always estimate a more accurate maximum tolerated dose (MTD) according to the exact toxicity profile under any toxicity profiles without additional cost or length of the trial. These cannot be accomplished in designs using a binary indicator of DLT, such as Standard 3+3 design, ID, and continual reassessment method (CRM). Moreover, our EID is relatively objective, model free, and simple to use. Our toxicity scoring system can also be applied to other designs, such as CRM and escalation with overdose control (EWOC), to improve their efficiency and accuracy in MTD estimation by utilizing all toxicities. Our novel toxicity scoring system and EID may help to begin a new era in which toxicity response is treated as a continuous variable.
منابع مشابه
Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS) is a novel Phase I design that integrates the novel toxicity scoring system originally proposed by Chen et al. [1] and the original Isotonic Design proposed by Leung et al. [2]. ID-NETS has substantially improved the accuracy of maximum tolerated dose (MTD) estimation and trial efficiency in the Phase I clinical trial setting ...
متن کاملDose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Escalation with overdose control (EWOC) is a Bayesian adaptive design for selecting dose levels in cancer Phase I clinical trials while controlling the posterior probability of exceeding the maximum tolerated dose (MTD). EWOC has been used by clinicians to design many cancer Phase I clinical trials, see e.g. [1-4]. However, this design treats the toxicity response as a binary indicator of dose ...
متن کاملDose-finding designs using a novel quasi-continuous endpoint for multiple toxicities
The aim of a phase I oncology trial is to identify a dose with an acceptable safety profile. Most phase I designs use the dose-limiting toxicity, a binary endpoint, to assess the unacceptable level of toxicity. The dose-limiting toxicity might be incomplete for investigating molecularly targeted therapies as much useful toxicity information is discarded. In this work, we propose a quasi-continu...
متن کاملBayesian Adaptive Designs for Early Phase Clinical Trials
BAYESIAN ADAPTIVE DESIGNS FOR EARLY PHASE CLINICAL TRIALS Publication No. Chunyan Cai, B.S. Supervisory Professor: Ying Yuan, Ph.D. My dissertation focuses mainly on Bayesian adaptive designs for phase I and phase II clinical trials. It includes three specific topics: (1) proposing a novel two-dimensional dose-finding algorithm for biological agents, (2) developing Bayesian adaptive screening d...
متن کاملClinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response.
Like other cancer therapy agents under development, radionuclide therapies are usually evaluated in a progressive series of clinical trials after basic science, human cell culture and animal model studies. Toxicities during these trials are graded using common scoring systems that are in widespread use such as the Common Toxicity Criteria from the National Cancer Institute. Information on norma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Contemporary clinical trials
دوره 31 5 شماره
صفحات -
تاریخ انتشار 2010